Course Description:
This course teaches key principles and concepts of industrial bioprocessing of protein, cell/gene, and mRNA therapies. The course covers recent technologies and practices of upstream, downstream, and analytical tools in the bioprocessing industry. In addition, FDA initiatives of PAT (Process Analytical Technology), Quality by Design, and Emerging Technology will be covered. This course is an excellent opportunity for biomanufacturing training and workforce development for both new and veteran workers in bio-tech.
Instructors:
Industry professionals from FDA, BMS, Pfizer, MilliporeSigma, UMass Biologics and UMass Lowell.
Date and Location:
Date: Monday July 28 – Friday, August 1, 2025, from 8:30 a.m. – 5 p.m
Location: UMass Lowell North Campus, Lowell, Massachusetts, Pulichino Tong Business Center, #120
Target Audience:
Scientist, Senior Research Scientist, Bioprocess Engineer, or equivalent in Pharmaceuticals, Biopharmaceuticals.
Attendees from academia and regulatory agencies may also benefit depending on their areas of interest and level of experience.
Course Objectives:
At the completion of this course, the participant will be able to:
Understand the recent technologies of upstream, downstream, and analytical tools used in the bioprocessing industry.
Explore advantages, disadvantages, and various applications in actively emerging cell and gene therapies along with their bioprocessing practices.
Learn Quality by Design (QBD) in regulatory and big
data analytics used in the biopharmaceutical
development and manufacturing field.
Registration:
Register here
For detail course information: See flyer
Cost of attendance: $3,840 for Industry; $2,880 for Advanced Mammalian
Biomanufacturing Innovation Center (AMBIC) and National Institute for Pharmaceutical Technology and Education (NIPTE) consortium members; $1,920 for Academia and Government employees
For questions please email: bpqc@uml.edu or Maurizio_Cattaneo@uml.edu.